Authors

Latest:

Dr. Sehgal on the Structure and Manufacturing Process of CAR T Cells

Alison Rager Sehgal, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the structure and manufacturing process of CAR T cells.

Alison Stopeck, MD, Rowan T. Chlebowski, MD, PhD

Latest:

SABCS Interview Series

The January issue of OBTN featured highlights from the 32nd Annual San Antonio Breast Cancer Symposium (SABCS). We wrap up our SABCS coverage this month with interviews on denosumab with Alison Stopeck, MD, associate professor of medicine at the University of Arizona and director of the Clinical Breast Cancer Program at the Arizona Cancer Center; oral bisphosphonates with Rowan T.Chlebowski, MD, PhD, professor and chief of the Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center; and adjuvant chemotherapyÃƒÂ¢Ã¯Â¿Â½Ã¯Â¿Â½induced alopecia with Hugues Bourgeois, MD, Centre Jean Bernard in Lemans, France.

Allen L. Cohn, MD

Latest:

Dr. Cohn on Frontline Therapies in Metastatic Pancreatic Cancer

Allen L. Cohn, MD, medical oncologist, Rocky Mountain Cancer Centers, discusses frontline therapies in metastatic pancreatic cancer.

Allen S. Lichter, MD

Latest:

Dr. Lichter on the Importance of the UN Summit on NCDs

Dr. Allen S. Lichter the chief executive officer of ASCO on the Importance of the UN Summit on NCD

Allie Casey

Latest:

Affordable Care Act Positively Affects Stage at Diagnosis

More Stage I cancers were diagnosed after the passage of the Affordable Care Act within five screenable disease types than were diagnosed before ACA implementation.

Allie Strickler

Latest:

AR Emerges as a Potential Target in Triple-Negative Breast Cancer

Whereas the androgen receptor (AR) is a common target in prostate cancer, emerging findings are showing a potential role for targeting AR in breast cancer, as well.

Allison Betof Warner, MD, PhD

Latest:

FDA Approval Insights: Afami-Cel for Pretreated, Unresectable or Metastatic Synovial Sarcoma

Dr Warner discusses the FDA approval of afami-cel for patients with advanced synovial sarcoma and key findings from the pivotal SPEARHEAD-1 trial.

Allison C. Rosenthal, DO

Latest:

Dr. Rosenthal on FDA Approval of Ibrutinib in Marginal Zone Lymphoma

Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses the FDA approval of of ibrutinib (Imbruvica) as a treatment for patients with marginal zone lymphoma (MZL).

Allison Inserro

Latest:

Oncology Payment Models Fall Short of Desired Goals

There is a year and a half remaining in the life of the Oncology Care Model, and although the Centers for Medicare & Medicaid Services has leapt forward with a vision for the next-generation model of care Oncology Care First, many stakeholders feel that the Oncology Care Model is more than enough to think about right now.

Allison Staley, MD, MPH

Latest:

Managing Obesity in Survivors of Gynecologic Cancer

With nearly 40% of the adult population in the Unites States classified as obese, gynecologic oncologists must be ready to address the specific needs and considerations for this population, including for patients who have entered survivorship.

Allison Tyler, RN, BSN, OCNÂ®, CCRP, Staff Nurse, Cleveland Clinic

Latest:

Immunotherapy: Personalized Treatment for Advanced Prostate Cancer

In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.

Allison W. Kurian, MD

Latest:

Dr. Kurian on Association of Ovarian Cancer Risk With Mutations Detected by Multiple-Gene Germline Sequencing

Allison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses an ongoing trial exploring the association of ovarian cancer risk with mutations detected by multiple-gene germline sequencing in 95,561 women.

Allyson Beach

Latest:

Internal Investigations May be Open to Court and Government Agency Scrutiny

Given a handful of recent cases, and a recent update to the CMS Voluntary Self-Referral Disclosure Protocol, it appears that the federal government may be using the existence of these audits as a means for demonstrating that the provider "knew or should have known" that fraud occurred.

Allyson Bryant, MD

Latest:

Survivorship and Chronic Pain Management for Cancer Pain

The rise in survivorship has increased chronic pain in the cancer pain population, the treatment of which has many fundamental differences when compared to acute and terminal cancer pain.

Allyson J. Ocean, MD

Latest:

Dr. Ocean on the Toxicities With SM-88 in Metastatic Pancreatic Cancer

Allyson J. Ocean, MD, discusses her experiences with SM-88 in patients with metastatic pancreatic cancer.

Allyson Ocean, MD

Latest:

Dr. Ocean on Determining Optimal Frontline Treatments for Metastatic Pancreatic Cancer

Allyson Ocean, MD, discusses determining the optimal frontline treatment of patients with metastatic pancreatic cancer.

Allyson Ocean, MD, Weill Cornell Medical College

Allyson Yates

Latest:

Changing the Face of Lung Cancer in Kentucky: New Program May Serve as National Model

The efforts of the Kentucky LEADS Collaborative offer a unique opportunity to change the face of lung cancer in Kentucky by harnessing new lung cancer care and control strategies.

Alok A. Khorana, MD

Latest:

Dr. Khorana on Rates of Young-Onset Pancreatobiliary Adenocarcinoma

Alok Khorana, MD, discusses increasing rates of young-onset pancreatobiliary adenocarcinoma.

Alon Altman, MD

Latest:

Dr. Altman on Neoadjuvant Chemotherapy in High-Grade Serous Carcinoma

Alon Altman, MD, associate professor, Department of Obstertrics, Gynecology and Reproductive Sciences, University of Manitoba, discusses neoadjuvant chemotherapy for patients with high-grade serous carcinoma.